Bayer's Strategic Pivot Faces Investor Scrutiny Amid Legal and Financial Pressures

Bayer's stock is oversold (RSI 23) as AGM votes on a minimal dividend amid litigation costs. Growth drivers like Nubeqa surge, but patent cliff and cash flow pressures loom.

Bayer's stock, trading at EUR 39.97, finds itself in a technically oversold position with an RSI of 23. This price point sits roughly 19% below its 52-week high, a stark contrast to the share's impressive 85% gain over the past year. The immediate catalyst for investor attention is the company's virtual Annual General Meeting on April 24, a key event preceding a mandatory quiet period for management communication.

The AGM agenda underscores the company's constrained financial position. Shareholders will vote on a proposed dividend of just EUR 0.11 per share, a minimal payout reflecting the urgent need to conserve cash. High provisions for ongoing litigation are a primary drain, forcing balance sheet repair to the top of the priority list. The meeting will also usher in a refresh of the Supervisory Board, with long-standing members Paul Achleitner and Colleen Goggins stepping down. Their proposed replacements bring fresh industry perspectives: Marcel Smits, former Asia head for Cargill, and Alfred Stern, the current CEO of Austrian energy group OMV.

Operationally, Bayer is navigating a critical transition. The company reported a slight increase in sales for 2025 to approximately EUR 45.6 billion. For the current year, management targets currency-adjusted revenue of EUR 45 to 47 billion, with an adjusted EBITDA forecast between EUR 9.6 and 10.1 billion. A major headwind is the full impact of the Xarelto patent cliff in 2026, which is expected to slash the anticoagulant's revenue by 35 to 40 percent.

Growth drivers, however, are gaining significant traction. The prostate cancer drug Nubeqa saw sales surge 57% in 2025 to EUR 2.4 billion, while the kidney medicine Kerendia grew 79% to EUR 829 million. Bayer anticipates both products will grow by another 50% in 2026. The pipeline also delivered positive news with the stroke prevention drug asundexian, which successfully met primary efficacy and safety endpoints in its Phase III OCEANIC-STROKE trial. Having received Fast Track designation from the FDA, Bayer is now preparing for regulatory submissions.

Further pipeline progress includes the global first approval in Japan for the MRI contrast agent gadoquatrane (Ambelvist), which is applicable for all body regions including newborns. Japan also approved Eylea 8 mg for a third retinal indication in March.

The company's financial outlook remains burdened by legacy issues. Free cash flow for 2026 is projected to be deeply negative at approximately minus EUR 5 billion, largely due to pending glyphosate settlement payments. Bayer's new organizational model is expected to contribute EUR 2 billion in positive earnings effects, and management states that potential US import tariffs on medicines have already been factored into its planning. The long-term ambition is to achieve an operating margin around 30% by the end of the decade.

All eyes will quickly shift to May 12, when the quiet period ends and Bayer releases its first-quarter 2026 figures. Analysts expect earnings per share of around EUR 2.22. More critically, this report will serve as the management's first official commentary on the status of major ongoing litigation, with key court decisions looming. This legal assessment may ultimately influence the stock's trajectory in the coming months more powerfully than any pipeline update.